This underscores the mutual good thing about partnering with LBDA in biomarker research. LBD may be the second most common form of degenerative dementia in older people, affecting around 1.3 million people in the usa. Yet many individuals who’ve LBD are misdiagnosed, mostly with Alzheimer’s or Parkinson’s illnesses. Developing effective biomarkers is paramount to helping to correctly diagnose the condition, monitor disease progression and develop effective brand-new drugs to treat, prevent and cure LBD. The advancement of dependable biomarkers for LBD is essential for both early diagnosis and the near future development of fresh LBD treatments, stated Angela Herron, LBDA Board President.The solution appears to be no’ . This content is certainly republished with kind permission from our close friends at The Kaiser Family members Foundation. You can view the entire Kaiser Daily Health Policy Record, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Daily Health Policy Report is released for Kaisernetwork.org, a free of charge service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Alere Analytics’ Fauzia Khan to provide keynote address at ACO Summit Alere Analytics, an Alere subsidiary specializing in analytics and clinical decision support technology, announced that Chief Medical Officer and Co-founder today, Dr.